Features of Cytotoxins and Immunotoxins for Cancer Therapy

• Compiles the latest information on cytotoxins and immunotoxins for cancer therapy into a single reference
• Summarizes the work and clinical trial data of leading researchers
• Describes the preclinical and clinical development of the first FDA-approved cytotoxin
• Discusses the preclinical and clinical trial development of numerous cytotoxins and immunotoxins

Contents

Pseudomonas Exotoxin (PE)-Based Immunotoxins/Cytotoxins

• Targeting of Pseudomonas Exotoxin-based Immunotoxins to Hematologic Malignancies
• Interleukin-4-targeted Cytotoxin for Recurrent Glioblastoma Therapy
• Interleukin-13 Receptors and Development of IL-13-Pseudomonas Exotoxin for Human Cancer Therapy

Ricin-Based Immunotoxins/Cytotoxins

• Ricin Immunotoxins in Lymphomas

Diphtheria Toxin (DT)-Based Immunotoxins/Cytotoxins

• Diphtheria-based Immunotoxins: Targeting Overexpressed Interleukin-13 Receptor and Urokinase-type Plasminogen Activator Receptor on Glioblastoma Multiformed
• DAB389IL-2 (Ontak): Development and Therapeutic Applications
• Transferrin Diphtheria Toxin for Brain Tumor Therapy
• GM-CSF Receptor Targeted Therapy of Human Leukemia
• VEGF-diphtheria toxin for Targeting of Tumor Blood Vessels
• MISCELLANEOUS
• cBR-96-doxorubicin (SGN-15) for Metastatic Breast Cancer Therapy
• Anti-CD33 Calicheamicin Immunoconjugate Therapy of Acute Myeloid Leukemiad

Index

click here to see books • videos • cd-roms of related interest